|
|
 |
|
Viewing report
|
|
|
|
2008 U.S. Drug Delivery: Neurological Disorders - Physician Perspective
Frost & Sullivan, Nov 2010, Pages: 45
This research service encompasses feedback on aspects of drug delivery and drug treatment provided by physicians in the U.S. who treat neurological disorders in order to enable interested stakeholders to gain insight into current and future prescribing and treatment trends. Analysis of the gathered data includes issues such as awareness, usage, preferences, influencing criteria, patient compliance, desired delivery types to be made available, as well as feedback on the role the delivery device plays in the prescribing decision for a drug
Research Overview
This Frost & Sullivan research service titled 2008 U.S. Drug Delivery: Neurological Disorders - Physician Perspective presents feedback on aspects of drug delivery and drug treatment provided by physicians in the United States who treat neurological disorders. This will enable interested stakeholders to gain insight into current and future prescribing and treatment trends. In this research, Frost & Sullivan's expert analysts thoroughly examine the following delivery types: autoinjectors, transdermal patch, oral drug delivery, and intravenous infusion.
Market Overview
Majority of Physicians in the United States Prefer to Prescribe Oral Drug Delivery for Neurological Disorders
Physicians in the United States treating neurological disorders – depression, Alzheimer’s disease, Parkinson’s disease, attention deficit hyperactivity disorder (ADHD), and schizophrenia – state that oral mode is their preferred drug delivery mode for treating patients. Oral, transdermal patches, injection, and topical gel/cream are the methods that doctors are most aware of, regardless of disease-specific usage. “Oral, injection, and transdermal patches are vehicles which most patients are expected to have high awareness (99 percent),” says the analyst of this research service. “An overwhelming 76 percent of physicians prefer oral drug delivery to other modes of administration for neurological disorders.”
A majority of physicians are willing to prescribe new drug delivery forms to their patients. Although 43 percent of physicians feel that they adopt new delivery forms earlier than their peers, 35 percent of them are very cautious about prescribing delivery forms that are new in the market. The physicians have cited the top five factors for selecting a drug delivery type as: minimal side effects, patient ease of use, patient convenience, patient satisfaction, and patient comfort.
There is some significant degree of preference for transdermal patches, especially for drugs that treat Alzheimer’s disease. “Transdermal patch is the second most preferred drug delivery for neurological disorders,” notes the analyst. “Injection and intravenous infusion are the least desirable methods for treating neurological disorders.” Potential for increase in usage appears to be highest for transdermal patch delivery, followed closely by oral. Among physicians who perceive certain drug delivery methods as currently unavailable for the treatment of neurological disorders, there is highest interest in products using transdermal patch, active transdermal, and implant delivery methods.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Autoinjectors
- Transdermal patch
- Oral drug delivery
- Intravenous infusion
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
